Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give Altimmune a “Moderate Buy” consensus rating: Seven of nine analysts recommend buying the stock, while one rates it a hold and one a sell. The average 12-month price target is $14.33, versus a recent share price of $3.11.
• Institutional ownership is substantial: Hedge funds and other institutional investors own approximately 78.05% of Altimmune’s outstanding shares, with several firms recently increasing their positions.
• Altimmune reported a quarterly loss of $0.12 per share, outperforming the consensus estimate of a $0.14 loss. Analysts expect a full-year loss of approximately $0.58 per share, while the clinical-stage biotech continues developing vaccines and therapies for infectious, liver and metabolic diseases.

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $14.3333.

A number of equities analysts recently issued reports on the company. Citigroup reissued a "market outperform" rating on shares of Altimmune in a report on Tuesday, June 2nd. HC Wainwright reissued a "buy" rating on shares of Altimmune in a report on Tuesday, July 28th. Citizens Jmp cut their price objective on shares of Altimmune from $14.00 to $11.00 and set a "market outperform" rating on the stock in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Altimmune in a report on Wednesday, June 24th. Finally, Wall Street Zen upgraded shares of Altimmune from a "strong sell" rating to a "sell" rating in a research report on Saturday, June 27th.

Hedge Funds Weigh In On Altimmune

Several hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. increased its stake in Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company's stock valued at $32,000 after purchasing an additional 1,928 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock worth $247,000 after purchasing an additional 2,241 shares in the last quarter. Concurrent Investment Advisors LLC grew its stake in shares of Altimmune by 10.4% in the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company's stock valued at $96,000 after buying an additional 2,500 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Altimmune by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company's stock valued at $108,000 after buying an additional 2,748 shares during the period. Finally, Deutsche Bank AG grew its stake in shares of Altimmune by 4.0% in the 4th quarter. Deutsche Bank AG now owns 79,940 shares of the company's stock valued at $289,000 after buying an additional 3,047 shares during the period. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Stock Performance

Shares of NASDAQ:ALT opened at $3.11 on Monday. The company has a market cap of $604.96 million, a PE ratio of -3.99 and a beta of 0.27. The company's 50-day moving average price is $2.99 and its 200 day moving average price is $3.23. Altimmune has a fifty-two week low of $2.56 and a fifty-two week high of $6.44. The company has a quick ratio of 26.78, a current ratio of 26.78 and a debt-to-equity ratio of 0.07.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 31.41%. Sell-side analysts anticipate that Altimmune will post -0.58 earnings per share for the current year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune's approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source